



- Molecular/Precision Oncology
- Biology of Leukaemia/Cancer Stem Cells
- Leukaemia/Cancer Biomarkers
- DNA damage-induced leukaemia
- Therapeutic targets of leukaemia stem cells
- Cancer Stem Cells Bio-banking

“no conflict of interest”

**อาจารย์ ดร. ชีระพงศ์ ศิริบุรณโพิพัฒน์**  
**วทบ. เทคนิคการแพทย์ มหาวิทยาลัยขอนแก่น**  
**วทม. พยาธิวิทยาคลินิก มหาวิทยาลัยมหิดล**  
**MRes in Biomedical Sciences (Biology of**  
**Cancer) The University of Liverpool,**  
**Liverpool, UK**  
**Mphil/PhD in Cancer Studies Research,**  
**King's College of London, London, UK**

**ห้องปฏิบัติการมนุษย์พันธุศาสตร์**  
**(Human Genetics)**



*If give you the world*

**KCL, 2011-2014,  
Biology of Leukaemia  
Stem Cells**

**2009, The Royal Thai Government Scholarship,  
Ministry of Science and Technology**

**U of LIV, 2010-2011,  
Pharmacogenomics of  
CML**


**KKU, 1998,  
HLA,  
Secretors genotyping**

**MU 2002, Forensic  
genetics & Molecular  
oncology, Current boss**

*May 2009*



# Concept of the origin of leukemia



“Leukemia initiating cell (LIC)/leukemia stem cell (LSC) can originate from both **HSC** and **progenitor cells**”





**Self-renewal** is fundamental and essential property of normal and cancer stem cells, and is absent in their downstream progenitors

**Both HSC and Progenitor cells can be targeted** by initial events (e.g., MLL fusions) to **become LSC** with acquisition of additional cooperative events (e.g. FLT3)

Self-renewal pathways such as  **$\beta$ -catenin** and **Hox**, which have differential effects on LSCs versus normal HSCs, may be **key targets to eradicate LSCs**


## Cell of Origin and Clonal Evolution model of Leukaemia Stem Cells








# Biology of multiple myeloma



PhD student




MSc student





## Acquired mutations of ABL tyrosine kinase domain in Ph+ CML after treatment with TKI (Rama cases from 2010-2014)



- ทูลอดหนุนการวิจัยศูนย์มะเร็งคณะแพทยศาสตร์โรงพยาบาลรามาธิบดี
  - The *JAK2V617F* mutation status and allele burden in Thai patients with polycythemia vera (PV) and essential thrombocythemia (ET) (published)
  - Correlation findings and frequency of *CALR* exon 9 mutations in wild type *JAK2* BCR-ABL negative MPN patients (under revision)
- ทูลนักวิจัยใหม่กระทรวงวิทยาศาสตร์และเทคโนโลยีปี พ.ศ.2559
  - The detection of somatic TP53 mutation in multiple myeloma;  
**asking for research students**

### Current MSc students



**RNA spliceosome  
mutations in MDS**



**Genetic alterations in  
multiple myeloma**

